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Abstract
Introduction: A significant proportion of high-risk breast cancer families are not explained by mutations in known
genes. Recent genome-wide searches (GWS) have not revealed any single major locus reminiscent of BRCA1 and
BRCA2, indicating that still unidentified genes may explain relatively few families each or interact in a way obscure
to linkage analyses. This has drawn attention to possible benefits of studying populations where genetic
heterogeneity might be reduced. We thus performed a GWS for linkage on nine Icelandic multiple-case non-
BRCA1/2 families of desirable size for mapping highly penetrant loci. To follow up suggestive loci, an additional 13
families from other Nordic countries were genotyped for selected markers.
Methods: GWS was performed using 811 microsatellite markers providing about five centiMorgan (cM) resolution.
Multipoint logarithm of odds (LOD) scores were calculated using parametric and nonparametric methods. For
selected markers and cases, tumour tissue was compared to normal tissue to look for allelic loss indicative of a
tumour suppressor gene.
Results: The three highest signals were located at chromosomes 6q, 2p and 14q. One family contributed
suggestive LOD scores (LOD 2.63 to 3.03, dominant model) at all these regions, without consistent evidence of a
tumour suppressor gene. Haplotypes in nine affected family members mapped the loci to 2p23.2 to p21, 6q14.2 to
q23.2 and 14q21.3 to q24.3. No evidence of a highly penetrant locus was found among the remaining families. The
heterogeneity LOD (HLOD) at the 6q, 2p and 14q loci in all families was 3.27, 1.66 and 1.24, respectively. The
subset of 13 Nordic families showed supportive HLODs at chromosome 6q (ranging from 0.34 to 1.37 by country
subset). The 2p and 14q loci overlap with regions indicated by large families in previous GWS studies of breast
cancer.
Conclusions: Chromosomes 2p, 6q and 14q are candidate sites for genes contributing together to high breast
cancer risk. A polygenic model is supported, suggesting the joint effect of genes in contributing to breast cancer
risk to be rather common in non-BRCA1/2 families. For genetic counselling it would seem important to resolve the
mode of genetic interaction.
Introduction
Increased susceptibility to breast cancer (BC) has been
shown to be caused by germline segregation of three
different classes of alleles: 1) high-penetrance genes with
rare risk variants, 2) moderate-penetrance genes, also
with rare variants and 3) low-penetrance alleles of
common frequency [1]. Hereditary BC, defined by a sig-
nificant familial aggregation of BC and explaining
approximately 5 to 10% of cases diagnosed with BC, is
as yet seen to arise from the first allele class whenever
the causative gene is known. Genetic counselling can
then be provided, based on mutation screening. A sig-
nificant proportion of the families are not associated
with mutations in BRCA1 or BRCA2 or other known
genes [2-5] and may in part be explained by recessive
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alleles or a polygenic model with risk variants of lower
penetrance jointly affecting risk in miscellaneous combi-
nations [6-8]. However, the gene most recently identi-
fied, RAD51C [9], demonstrates that some proportion
may still have a high-risk-allele cause. RAD51C was
identified using a candidate gene approach, but if more
high-penetrance genes are yet to be identified it might
also be helpful to analyse families from populations
where genetic heterogeneity might be reduced [10,11].
Recent genome-wide searches (GWS) for BC linkage in
families without alterations in known genes (non-
BRCA1/2 families) [10-16], together with earlier sugges-
tions of single loci [17-19], indicate close to 20 candi-
date chromosome regions if accepting LOD scores ≥ 1.5
found in a single family or small group of families [16].
Two regions have been independently pinpointed by
more than one study, one on chromosome 2p21 to p22
[11,13] and the other at 6q24 where the ESR1 gene is
located [16,19]. In some studies, notable linkage signals
have been seen at two or three chromosome regions in
the same family [11-13,16], which by chance would have
a low probability [15].
Two issues helped shape our current GWS study. First,
both BRCA1 and BRCA2 are tumour suppressor genes
and most often involve wild-type loss of heterozygosity
(wt-LOH) in mutation carriers’ tumours [20,21], resulting
in both parental copies of the gene being damaged in line
with Knudson’s two-hit model [22]. Any new loci sugges-
tive by large families to confer high-risk of BC would
predictably gain support from the observation of such a
wt-LOH signature; on the other hand, the lack of it
would leave open the question of different gene func-
tions. Second, in Iceland both BRCA1 and BRCA2 have
been found with recurrent mutations, one in each gene,
with the BRCA2-999del5 mutation occurring in 8.5% of
BC patients and 0.5% of the population [23-25]. Other
mutations in these genes in Iceland have not been pub-
lished and would presumably be very rare [3]. This
accords with the relative geographical isolation of the
Icelandic population which since the settlement of the
island in the ninth century has at times suffered famine-
or epidemic-caused reductions (with population size only
38,000 in the year 1800 compared to the current size of
319,000), which in effect should reduce the complexity of
a gene search. We therefore selected nine large Icelandic
non-BRCA1/2 families for a GWS of high-risk genes
under a parametric dominant linkage model. Regions
considered suggestive (LOD ≥ 1.5 per family) were also
subjected to wt-LOH analyses in tumours from putative
gene carriers, and the same regions were genotyped in a
collection of Nordic non-BRCA1/2 families, in order to
estimate the possible proportion of linked families in Ice-
land and other Nordic countries.
Materials and methods
After screening for recurrent Icelandic BRCA1 and
BRCA2 mutations in 438 BC cases diagnosed in Iceland
in the years 1989 to 2001, the history of BC was evalu-
ated in the pedigrees of both the mother’s and the
father’s family side of the non-BRCA1/2 cases. Nine
families were selected and subjected to a GWS of BC
linkage by the selection criteria of (1) at least three
women diagnosed with BC under age 60 years (omitting
bilineal cases), (2) the availability of blood or paraffin-
embedded normal tissue for isolation of DNA of suffi-
cient quality from at least four affected cases (any age),
and (3) evidence against linkage to BRCA1 or BRCA2
according to genotyped microsatellite markers flanking
and within these genes. Each of the nine families con-
sisted of descendents of a single pair of founders. In five
families a DNA sample was available from six or more
BC cases (Additional file 1, Figure S1). In the analyses,
the nine families were treated as 12 because three pedi-
grees (70070, 70228 and 70236) were too large for the
GWS linkage analysis software and were therefore sepa-
rated by branches in two parts each (Additional file 1,
Figure S1). The two family sides were compared by
inspection of LOD signals (selection of peaks based on
NP-LOD related P-values) in order to find possibly
overlapping positions, which could then be further
examined by manual comparison of haplotypes.
Thirteen additional Nordic families were used in follow-
up studies on suggestive loci on chromosomes 2p, 6q and
14q. They were selected from available non-BRCA1/2
families at other Nordic centres, in line with the above cri-
teria and in such a way that the genotyped affected family
members would not be expected to share by descent more
than approximately 6% of alleles by chance (through at
least six meioses). Written informed consent was obtained
with all blood samples and appropriate Institutional
Review Board approvals were obtained. Characteristics of
the 22 families are summarised in Table 1 and further
details about the families included in the GWS are pro-
vided in Figure S1 (Additional file 1).
DNA was extracted from nuclei of lysed blood sam-
ples according to Miller et al. [26] or by standard phe-
nol-chloroform extraction, from fresh-frozen tissue
using the Wizard Genomic DNA Purification Kit (Pro-
mega, Madison, Wisconsin, USA) and from paraffin-
embedded tissue using a xylene treatment followed by
proteinase K digestion and phenol/chloroform/isoamyl
alcohol purification. All genotyping was performed at
the same centre; each sample plate contained a blank
well, two duplicate samples and a Centre d’Etude du
Polymorphisme Humain (CEPH) control. Samples
included in the GWS were genotyped using the Applied
Biosystems (Foster City, California, USA) HD-5 Linkage
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Mapping Set, containing 811 fluorescently labelled PCR
primer pairs that define an approximately five centiMor-
gan (cM) resolution human index map. Genotypes were
analysed using an automated ABI PRISM 3130 × l
Genetic Analyzer with GeneMapper software v4.0
(Applied Biosystems, Foster City, California, USA) for
automatic calling of alleles, and then checked manually.
For LOH analysis (eight members of family 70234),
DNA was also isolated from tumour tissue, which was
obtained from paraffin blocks (invasive primary
tumours) after selecting areas rich in tumour cells (>
90%) by microscopy (all by the same investigator) and
relative allele intensities were then compared to those of
blood or normal-tissue from the same individual. For six
women, this tumour DNA or DNA from fresh-frozen
tissue was also subjected to array comparative genomic
hybridisation (array-CGH). Arrays were produced at
SCIBLU Genomics, Lund University as previously
described [27] using the 32K tiling BAC clone set from
the CHORI BACPAC resource centre.
Merlin software (Center for Statistical Genetics, Uni-
versity of Michigan, Ann Arbor, Michigan, USA) [28]
was used for the linkage analysis. Four different multi-
point analyses were carried out and associated LOD
scores calculated: (i) parametric dominant and (ii) reces-
sive with age dependent liability classes (14 total) as
defined using the modified Cancer and Steroid Hor-
mone Study (CASH) model [29]; cf. [4,30], (iii) non-
parametric using S-all scoring [31] and (iv) S-pairs scor-
ing [32], in both cases with the exponential model [33].
Only cases with invasive BC were coded as affected; all
other cancers were assigned with unknown status. Two
affected cases in one family (70234) were identical twins
and only one of them was included in linkage calcula-
tions. For parametric linkage heterogeneity LOD scores
(HLOD) are reported. Under the parametric models dis-
ease allele frequencies of 0.0033 (dominant) and 0.08
(recessive) were assumed as in [29]. The Rutgers Map
v.2 [34] (which is based on the deCODE map [35]) was
used to locate markers, and if not present in that map
they were placed with linear interpolation using their
physical position in base pairs relative to flanking mar-
kers. Allele frequencies were estimated separately for
each country by counting in all individuals (the -fa
option of Merlin). LOD scores for individual families
were also calculated, by running each family separately
in Merlin, but using allele frequencies of the total sam-
ple of the relevant country. Genotypes that were incom-
patible with the family relations (inheritance errors), as
well as unlikely genotypes, were eliminated with the
help of Merlin software.
In order to analyse conditional probabilities by family
of being linked under the admixture model, the files
prepared by Merlin software were reformatted to fit
LINKMAP software (National Center for Biotechnology
Information (NCBI), Bethesda, Maryland, USA) for slid-
ing three-point linkage analysis of selected markers.
Eighteen markers were analysed at 6q, 16 at 14q and 7
at 2p, using country-specific allele frequencies. Disease
allele frequency and age dependent liability classes were
as above, under the dominant model [29,30].
The probability of two or three haplotypes from inde-
pendently segregated chromosomal regions (a priori
unknown positions), being simultaneously cosegregated
with a trait through m meioses, in one out of N families
with similar or greater total number of meioses (Bonfer-
roni adjustment), was calculated as described (Addi-
tional file 2). Briefly, the resulting P-value for two loci is
P m= × × −N 495 20 0 25. (1)
and for three loci
P m= × × −N 1617 125 200 0. (2)
Results
Nine Icelandic BC families, unexplained by BRCA1 or
BRCA2 mutations (non-BRCA1/2 families), were geno-
typed for a set of 811 genome-wide distributed
Table 1 Summary of families by group
Number of families
Group Total Number of cases of BC Cases with age at onset < 50 y Number of genotyped
individuals (affected)
4 5 6+ < 4 4+
Iceland* 9 (12) 0 (1) 2 (6) 7 (5) 6 (10) 3 (2) 102 (60)
Lund/Oslo 3 3 1 2 31 (14)
Helsinki 7 1 4 2 5 2 56 (31)
Oulu 3 1 1 1 3 20 (15)
Total 22 2 7 13 15 7 208 (119)
* Except for the last column, numbers within parentheses refer to the number of families as processed in linkage calculations, in which three families were
separated in two parts each due to large size (see Additional file 1, Figure S1).
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microsatellite markers for subsequent linkage analysis.
As all pedigrees appeared high-risk and dominant, the
main analysis was based on the parametric dominant
model but other models were also considered in order
to see if the LOD scores were sensitive to model mis-
specification. Figure 1a, b shows LOD scores for para-
metric and non-parametric linkage analysis by
chromosomal position for the nine families combined.
For comparison, the position of the main indications of
BC susceptibility according to previously published stu-
dies of non-BRCA1/2 linkage is shown in Figure 1c.
Two of three regions with dominant HLOD > 1.5 over-
lap with previously indicated loci. One of them maps to
2p and contains two separate peaks (peak HLOD 1.72 at
D2S162 and 2.41 at D2S367; both peaks overlapping
with previous indications) and the other to 14q (HLOD
1.68 at D14S63). However, the third region, at 6q
(reaching HLOD 2.44 at D6S300) does not overlap with
previously reported candidates (Figure 1a-c).
When analysing separate families, one (named 70234)
was seen to contribute high scores (LOD 2.63 to 3.03)
at all three major positions, 2p, 6q and 14q (Figure 1d).
At 6q and 14q haplotypes of 29 and 13 Mb DNA,
respectively, were shared by all nine non-BRCA1/2 BC-
affected women in this family and eight of these women
also shared a haplotype (9 Mb) at 2p (Figure 2). With
reference to the flanking (recombined) markers, the
common haplotypes map to 2p23.2 to p21 (between
D2S165 and D2S2259), 6q14.2 to q23.2 (between
D6S1609 and D6S262) and 14q21.3 to 24.3 (between
D14S288 and D14S1036). A close inspection of the
information in Figure 2 makes it is evident that the 6q
and 14q haplotypes are identical by descent and have
cosegregated through 13 meioses, and that the 2p haplo-
type has cosegregated with the other two through 11
meioses. Of the nine families, a total of five had a com-
parable total number of meioses connecting the affected
cases (ranging from 13 to 18). Therefore a Bonferroni
correction of N = 5 has been chosen. By formula (1) the
probability of observing cosegregation of two loci (6q
and 14q) through 13 meioses in one of five families is
P = 0.006. The corresponding probability for all three
loci and 11 meioses is also P = 0.006 (formula (2)). We
also used Merlin to simulate marker data in order to get
an indication of the frequency of obtaining three sepa-
rate dominant model LOD scores > 2.5. A total of 700
replicates of the per-family runs were generated using
the same allele frequency estimates as in the original
Figure 1 Maximum LOD scores by chromosomal position, and relation to previously suggested candidate loci. Parametric HLOD scores
for the nine Icelandic families are shown in (a) for the dominant (dark teal thick line) and the recessive model (plum). NP-LOD scores are shown
in (b) using different exponential scoring options in Merlin software: S-all (orange thick line) and S-pairs (indigo). The position of previously
published loci is shown in (c), according to GWS studies in red (or black if reported in more than one GWS study) (adapted from Table 5 in
[16]), and according to single locus reports [17-19] in blue. A position at 2p indicated by a subset of relatively early-onset multiple-case families
in one GWS-study [11] is included in (c) and shown in grey. Parametric LOD scores of family 70234 are shown in (d) with line colours as in (b).
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run. In none of the replicates did we obtain a family
with three peaks of this magnitude, in two instances
there was a family with two peaks, in 75 instances we
obtained a family with one location with dominant LOD
> 2.5 (in six instances a family exceeding LOD 3.0), and
in the remaining simulated cases no dominant LOD >
2.5 was obtained.
Eight breast tumours from family 70234 were assayed
at markers within the shared haplotypes, for loss of het-
erogeneity selective for losing wild-type alleles (wt-LOH)
in harmony with Knudson’s model of tumour suppres-
sor genes. At 6q, LOH was seen at all informative mar-
kers in three tumours, with wt-LOH in two but the
third lost all alleles from the risk-related haplotype (data
not shown). Copy-number loss of the region was con-
firmed in the three tumours by array-CGH (data not
shown) which also revealed amplification at 6q21 in a
fourth tumour. At 2p and 14q, signs of allelic losses
were confined to single markers and of inconsistent alle-
lic phase (three tumours each chromosome), and not
supported by array-CGH since intensities were generally
within thresholds.
Family-wise, no other family than 70234 showed para-
metric LOD scores higher than 1.5 (and the highest NP-
LOD for the other families was 2.3). LOD scores of
weaker indication were seen at multiple positions
Figure 2 Cosegregation of haplotypes at three chromosomal regions in family 70234. On top, the pedigree of this family is shown with
circles denoting females and boxes males, with red filling denoting diagnosis of BC and shaded red also ovarian cancer. The pedigree is
somewhat distorted in order to avoid recognition, but preserves the number of male and female meioses. Information about approximate age
(in years) at diagnosis of cancer is shown below symbols (Br for breast and Ov for ovarian). One woman inherited a 999del5 BRCA2 mutation
from her father (red box), not otherwise blood-related to this family. This woman and one other (denoted by not GWS) were not included in the
genome-wide search. One of a pair of identical twins was omitted in linkage calculations. Under the pedigree, genotypes of markers of interest
are shown (with chromosomal band position, marker names and genomic distance shown at the left, brackets indicating position between sites
of relevant recombination). Colouring of alleles denotes whether they belong to a shared haplotype (allele frequency shown in the rightmost
column) or derive from a recombined chromosome (blue). Plain (not coloured) alleles denoted 11 and 3 at D2S367 and D2S2163 respectively,
are identical by state, but probably not by descent, to the commonly segregated allele (conclusion supported by fine-genotyping of additional
markers, data not shown). The low frequency (0.06) of the shared D6S434 allele was validated by typing in 59 unrelated Icelandic control
individuals. This figure was 0.02 in the controls (2/118), which coincides with the published Genethon frequency of the allele.
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(Additional files 3 and 4, Figures S2 and S3). In order to
see if any position might be indicated by more than one
family, even if too weakly suggestive on a single-family
basis, we listed all peaks that met the criterion of NP-
LOD associated P-values of < 0.005 (Additional file 5,
Table S1). Of 22 peaks, one was found to colocate with
that of family 70234 to the 6q15 to q22 region and two
families shared peaks at 13q32.1 to q33.1. In case of
separate parts of the same pedigree, possibly overlapping
peaks were not observed.
To follow up suggestive linkage signals (HLOD > 1.5
by family), markers at 2p, 6q and 14q were genotyped
in an additional 13 Nordic non-BRCA1/2 families.
Dominant parametric HLOD scores for the 13 families
combined reached 0.92 at D6S434, and were much
lower at 2p and 14q (highest HLOD 0.23 at D2S165).
An analysis of heterogeneity, using LINKMAP was per-
formed on all 22 Nordic families (treated as 25 for the
reasons given above) at the three chromosomal posi-
tions and the results are shown in Table 2. At chromo-
some 6q15 to q22.31, the combined HLOD was 3.27
and a 0.40. The data show support for chromosome
6q-linkage among both Icelandic and non-Icelandic
families. HLODs by country subset were in the range
0.34 to 2.02 (a ranging between 0.39 and 1). Single
families with a conditional probability of being linked
exceeding the overall a-value of 0.40 (10 families) were
widely distributed among the Nordic subsets (Table 2).
At chromosome 14q21.2 to q24.3 the main support for
linkage lies within the Icelandic subset (Table 2) with
HLOD 1.24 and a 0.36, unaltered by the addition of
other Nordic families. At 2p23.2 to p21 most non-Ice-
landic families fail to support the findings since they
indicate a more telomeric position (Table 2) which
does not overlap with the high peak in family 70234.
An exception is one Finnish family with LOD 1.03,
matching the position in family 70234. It has a
conditional probability of being linked equal to 0.78
(data not shown), only exceeded by that of family
70234 (0.97).
Discussion
In the present GWS for BC linkage in nine Icelandic
non-BRCA1/2 families, substantial linkage signals were
observed at chromosomes 2p25.1 to p22.1, 6q15 to
q22.31 and 14q21.3 to q31.3, and the strongest contri-
bution to all three regions occurred in the same family
(70234). On a single family basis, all three signals in
the family are exceptionally high compared to previous
studies [10-19], but none of the signals meet the
suggested cut off level of 3.3 for significance in GWS
studies [36]. The regions at 2p and 14q overlap with
those of previous studies of non-BRCA1/2 families.
The position of the more centromeric signal in our 2p
region (2p23.3 to p21) was in fact pinpointed on the
basis of single families by two independent studies
[11,13]. The more telomeric signal in our 2p region
(p25.1 to p24.1) contains a position with relation to
families with a higher number of cases and at a
younger age at diagnosis [11]. The region at 6q15 to
q22.31 does not extend to the 6q24.3 to q25.1/ESR1-
region [16,19] and does therefore not overlap with pre-
vious indications. This region had the strongest signal
(HLOD 3.27 in all families combined) in the current
study and gains support from some other families
besides 70234, both Icelandic and from other Nordic
countries (Table 2).
Recent studies have indicated familial non-BRCA1/2
BC as mainly polygenic with decreasing possibility of
finding new high-risk genes. Our results support this
view in the following way: The current study was pri-
marily designed to find whether dominant mutations of
high penetrance exist in large Icelandic non-BRCA1/2
families with a Mendelian pattern concurrent with such
Table 2 Peak parametric multipoint LOD scores under heterogeneity, at three chromosomal regions as defined by
family-70234 haplotypes
6q15 to q22.31 14q21.2 to q24.3 2p23.2 to p21
Subset Number
of
families*
HLOD a cM from
D6S434†
Number of
linked
families‡
HLOD a cM from
D14S980†
Number of
linked
families‡
HLOD a cM from
D2S367†
Number of
linked
families‡
Icelandic 12 2.02 0.45 -5.4 3 1.24 0.36 30.2 4 2.13 0.61 0.0 7
Lund/
Oslo
3 1.37 0.79 0.3 2 0 0 0.46 1.00 -14.4 0
Helsinki 7 0.34 0.39 12.2 3 0.06 0.34 22.2 0 1.09 1.00 -13.1 2
Oulu 3 1.15 1.00 -1.9 2 0 0 0.75 1.00 -7.5 1
Total 25 3.27 0.40 0.0 10 1.24 0.36 30.2 4 1.66 0.25 0.0 10
*Three Icelandic pedigrees were separated in two parts each in the linkage calculations. Therefore the total number of families in this table is 25.
†For each locus, the distance relates to the marker closest to the LOD-peak in family 70234; negative numbers refer to the direction towards the p-telomere.
‡Linked families are defined as having a conditional probability of linked type (data not shown) exceeding the alpha for all families combined.
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genetic explanation. Most families failed to reveal evi-
dence of any such locus. Although three chromosomes
provided suggestive linkage signals, their coexistence in
one family hardly supports the idea of a single causative
gene. Some families have previously been reported with
two or three suggestive chromosome regions [11-13,16]
and such an observation was shown to have a low prob-
ability simply by chance [15]. We do not consider chro-
mosomal translocation to be a logical possibility since
the three haplotypes in question segregate independently
to the daughters of affected cases in family 70234
(Figure 2). We estimate the probability to be P = 0.006
of seeing any two loci that are not linked to each other
cosegregate by chance with the disease through 13
meioses as here seen at 6q and 14q. This would argue
for the existence of more than one causative gene in
family 70234. Whether the third locus (2p), which also
cosegregates to eight of the nine cases, plays a role in
the risk is a little more ambiguous. Although the ninth
case inherited some alleles identical with the common
haplotype (and therefore contributed to the high LOD
of 2.63) they were on closer scrutiny (genotyping of
added markers, data not shown) seen to be interrupted
by non-matching alleles and therefore she should be
regarded as a phenocopy with respect to possible 2p-
linkage. By formula (2), the probability of observing
cosegregation of three loci through 11 meioses in one
of five families is P = 0.006. Although this might be
adjusted with respect to different possible ways of
observing a phenocopy, and to the fact that the pheno-
copy did inherit two of the three haplotypes, the
resulting value would still be on the same order as the
compared value for two loci. The 2p-haplotype may
therefore be irrelevant to the BC risk but it gains sup-
port from the two previous reports of a candidate BC
susceptibility locus which overlaps with this 2p-region
[11,13].
It may be asked if the unique triple strong signals in
family 70234 as compared to other families possibly
reflect distinction by genetic linkage models. The
absence of notable linkage peaks in the remaining
families conforms to a polygenic model with frequent
alleles, sometimes cosegregating and sometimes being
replaced by variants of different lineage or of other
genes. Family 70234 seems to differ in this respect,
even if questioning the 2p-linkage, since the two hap-
lotypes at 6q and 14q fully cosegregate with the dis-
ease in nine cases, with maximum LOD ranging from
2.74 to 3.03. Therefore a replacement of one haplotype
by a new variant (if needed) would appear to be a rare
event in this instance, and one might expect a low
population frequency of the gene variants involved.
This would have implications for genetic counselling,
since continued cosegregation of the two (not to men-
tion three) haplotypes would seem improbable for the
descendants of family 70234. It would then also be
important to resolve whether each of the genetic var-
iants contributes an independent proportion of the dis-
ease risk (additive or multiplicative joint effects), or in
an interdependent way, their risk being dependent on
the presence of all cofactors. With such a scenario,
one would view this family’s cancer history mainly as a
very rare chance result of cosegregation of limited con-
sequence for later generations of the family. Alterna-
tively, the families studied here may all comply with
the same genetic model, with cooperative alleles of
moderate or high frequency, and the strong linkage
signals in family 70234 to be accounted for by the
absence of phenocopies. We note, in this context, that
by treating the nine families as 12 for linkage calcula-
tions, most were not as highly informative by the num-
ber of cases or meioses as 70234, but nevertheless they
were expected to reveal clues of genomic position by
pairwise comparison of separate parts of the larger
pedigree.
The additional Nordic families support the risk indica-
tion of chromosome 6q, but seem not to support the
2p- and 14q-linkage. One Finnish family may be of the
linked type at the same 2p position as family 70234 but
this is not higher than expected by chance from 13
families, each with up to 6% sharing, by descent, of
genetic material between its affected members. The 6q-
linkage gains some support from other Icelandic families
(for example, 70386 in Additional file 5, Table S1). This
raises the question whether a recurrent mutation may
be involved, but comparison of haplotypes in suggestive
carriers from different families did not support that idea
(data not shown). If present, such a recurrent mutation
would seemingly call upon the genotyping of more den-
sely distributed markers.
At chromosome 2p, a linkage signal in the combined
families, telomeric to the one in family 70234 and con-
current with the reported position of a signal in rela-
tively early-onset multiple-case families [11], also invites
searching for an underlying recurrent mutation in the
Icelandic families. However, although some families con-
tribute to this signal with weakly positive LOD scores
(Additional files 3 and 4, Figures S2, S3), they lack reli-
able indications of which alleles to look for, partly due
to absence of a convincing ‘reference’ family (like 70234
in the case of 6q) and partly due to uncertain recombi-
nation events, and such comparison of haplotypes is
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therefore meaningless. In short, a sign of a recurrent
mutation (that is, alleles of not too high frequency, seen
in different candidate families) would support a risk
related role of this locus, but it is not seen.
As regards the three chromosome regions most
strongly indicated in our study, we tested by wt-LOH
analysis whether the genes in question might act as clas-
sical tumour suppressors. Three out of eight tumours
from family 70234 showed extensive LOH at 6q but it
affected both wild-type and risk related haplotypes. At
2p and 14q, convincing signs of LOH were absent.
Therefore no support was found for the hypothesis of a
predisposing tumour suppressor gene similar to the
BRCA1 and BRCA2 genes [20,21]. We note, however,
that the hypothesis is not ruled out because microaltera-
tions could exist that are not seen by our methods.
With respect to the four different ways used to analyse
linkage, we had reasons to choose the parametric domi-
nant analyses as the principal one. Looking at the pedi-
grees none appeared recessive. We also expected low
genetic heterogeneity. That would argue for s-all to be
the primary non-parametric method but for comparison
we also performed s-pairs analyses. By considering all
four analyses (Figures 1 and Additional files 3 and 4,
Figures S2, S3), the parametric dominant analyses did
not appear to be sensitive to model misspecification.
The results of our GWS analysis support previously
reported indications of a polygenic nature of non-
BRCA1/2 hereditary BC. Most families in the current
study fail to provide map indications of involved loci
and this may in part be credited to the problem of
phenocopies, which was addressed by simulation
experiments on BRCA1/2 families in the GWS study of
Rosa-Rosa et al. [16]. Finding more families with signals
analogous to those of 70234 in the current study could
provide further clues where to look for interacting risk
loci and a follow-up of more generations could then
help to resolve the significance and mode of possible
genetic interaction.
Conclusions
The results of this study support previous indications
that susceptibility to BC in multiple-case non-BRCA1/2
families seems to be segregated by low- or moderate-
penetrance gene variants jointly contributing to the risk.
A combination of variants at chromosomes 2p, 6q and
14q may in a cooperative or even interdependent way
cause high disease risk in a family. Together with other
such families reported with multiple linkage signals, this
may reflect localised familial clustering of risk alleles
from a pool of many candidate loci. Genetic counselling
would benefit from resolving the mode of interactions
in such families.
Additional material
Additional file 1: Figure S1, pedigrees of the families in the GWS.
This is a jpg file showing pedigrees of the families included in the GWS.
Pedigrees of nine Icelandic non-BRCA1/2 families with each showing BC
cases traced to a single pair of founders but otherwise omitting relatives
if not genotyped. Genotyped family members are marked with an
asterisk. Circles denote females and boxes males, with red filling
denoting diagnosis of BC and shaded red also ovarian cancer. Tan filling
indicates cancer at other sites than breast, or of unknown origin.
Information about the site and approximate age (in years) at diagnosis of
cancer is shown below the symbols (Br for breast, Col colon, Cvx cervix,
Kdn kidney, Lng lung, Ov ovary, Pnc pancreas, Pro prostate, Stm stomach
and Unkn for unknown origin). Dotted vertical lines between family
branches show how the family was separated in two parts for linkage
calculations. Pedigrees are somewhat distorted in order to avoid
recognition.
Additional file 2: Supplementary methods. A Word document
containing a methodological description of intra-family significance
testing for multiple loci.
Additional file 3: Figure S2, parametric LOD scores by family. A jpg
file showing graphs of parametric LOD scores by chromosomal position,
for the families in the GWS (the top graph with all families combined, for
comparison). LOD scores are shown for the dominant (dark teal line) and
the recessive model (plum). Three families (70070, 70228 and 70236)
were separated in smaller units for linkage analysis, as indicated by
adding the letter a or b to the family name.
Additional file 4: Figure S3, NP-LOD scores by family. A jpg file
showing graphs of NP-LOD scores and associated P-values by
chromosomal position in individual families included in GWS, using
different exponential scoring options in Merlin software: S-all (orange
thick line) and S-pairs (indigo). Three families (70070, 70228 and 70236)
were separated in smaller units for linkage analysis, as indicated by
adding the letter a or b to the family name.
Additional file 5: Table S1, Maximum LODs by chromosome and
family, for NP-LODs with P < 0.005. A Word file containing a table of
per-family LOD signals (selected with respect to NP-LOD associated P-
values), for consideration of whether any chromosomal positions may be
indicated by more than one family.
Abbreviations
BC: breast cancer; GWS: genome-wide search/genome-wide scan; HLOD:
heterogeneity LOD (parametric); LOD: logarithm of odds; LOH: loss of
heterozygosity; non-BRCA1/2: not accounted for by mutations in BRCA1 or
BRCA2 or other known genes; NP-LOD: non-parametric LOD; wt-LOH: LOH
with loss from the “wild-type” chromosome.
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